| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5418226 | ORGANON USA INC | Monoquaternary 2,16-bispiperidinylandrostane derivatives |
Apr, 2013
(11 years ago) | |
Raplon is owned by Organon Usa Inc.
Raplon contains Rapacuronium Bromide.
Raplon has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Raplon are:
- US5418226
Raplon was authorised for market use on 18 August, 1999.
Raplon is available in injectable;injection dosage forms.
The generics of Raplon are possible to be released after 14 April, 2013.
Drugs and Companies using RAPACURONIUM BROMIDE ingredient
Market Authorisation Date: 18 August, 1999
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
RAPLON family patents
